Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017
05 Janvier 2017 - 10:01PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today
that it will host a conference call and live webcast on Friday,
January 6, 2017 at 8:00 a.m. ET.
In order to participate, please dial the following numbers (at
least 10 minutes before the scheduled start time): United States
1-866-966-1396; Canada 1-866-992-6802 or International +44(0) 2071
928000; passcode: 44010191. For a list of other international
toll-free numbers, click here.
A live webcast of the call will also be available on Teva's
website at: www.ir.tevapharm.com. Please log in at least 10 minutes
prior to the conference call in order to download the applicable
audio software.
Following the conclusion of the call, a replay of the webcast
will be available within 24 hours on the Company's website. The
replay can also be accessed until February 5, 2017, 9:00 a.m. ET by
calling United States 1-866-247-4222; Canada 1-866-878-9237 or
International +44(0) 1452550000; passcode: 44010191.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients
every day. Headquartered in Israel, Teva is the world’s largest
generic medicines producer, leveraging its portfolio of more than
1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2015 amounted to $19.7
billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U.S. Private
Securities Litigation Reform Act of 1995:
This press release contains forward-looking statements, which
are based on management’s current beliefs and expectations and
involve a number of known and unknown risks and uncertainties that
could cause our future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our specialty
products, especially Copaxone® (which faces competition from
orally-administered alternatives and existing and potential generic
versions); our ability to integrate Allergan plc’s
worldwide generic pharmaceuticals business (“Actavis Generics”) and
to realize the anticipated benefits of the acquisition (and the
timing of realizing such benefits); the fact that following the
consummation of the Actavis Generics acquisition, we are dependent
to a much larger extent than previously on our generic
pharmaceutical business; potential restrictions on our ability to
engage in additional transactions or incur additional indebtedness
as a result of the substantial amount of debt incurred to finance
the Actavis Generics acquisition; the fact that for a period of
time following the Actavis Generics acquisition, we will have
significantly less cash on hand than previously, which could
adversely affect our ability to grow; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters;
our ability to achieve expected results from investments in our
pipeline of specialty and other products; our ability to identify
and successfully bid for suitable acquisition targets or licensing
opportunities, or to consummate and integrate acquisitions; the
extent to which any manufacturing or quality control problems
damage our reputation for quality production and require costly
remediation; increased government scrutiny in both the U.S.
and Europe of our patent settlement agreements; our
exposure to currency fluctuations and restrictions as well as
credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property
rights of our specialty medicines; the effects of reforms in
healthcare regulation and pharmaceutical pricing, reimbursement and
coverage; competition for our generic products, both from other
pharmaceutical companies and as a result of increased governmental
pricing pressures; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability,
major hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with
internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant
disruptions of our information technology systems or breaches of
our data security; competition for our specialty pharmaceutical
businesses from companies with greater resources and capabilities;
the impact of continuing consolidation of our distributors and
customers; decreased opportunities to obtain U.S. market
exclusivity for significant new generic products; potential
liability in the U.S., Europe and other markets for sales
of generic products prior to a final resolution of outstanding
patent litigation; our potential exposure to product liability
claims that are not covered by insurance; any failure to recruit or
retain key personnel, or to attract additional executive and
managerial talent; any failures to comply with
complex Medicare and Medicaid reporting and payment
obligations; significant impairment charges relating to intangible
assets, goodwill and property, plant and equipment; the effects of
increased leverage and our resulting reliance on access to the
capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits,
or of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the
most efficient manner; environmental risks; and other factors that
are discussed in our Annual Report on Form 20-F for the year
ended December 31, 2015 and in our other filings with
the U.S. Securities and Exchange Commission (the
"SEC").
Forward-looking statements speak only as of the date on which
they are made and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are advised, however, to consult any additional disclosures we
make in our reports to the SEC on Form 6-K. Also note
that we provide a cautionary discussion of risks and uncertainties
under “Risk Factors” in our Annual Report on Form 20-F for the year
ended December 31, 2015. These are factors that we believe
could cause our actual results to differ materially from expected
results. Other factors besides those listed could also adversely
affect us. This discussion is provided as permitted by the Private
Securities Litigation Reform Act of 1995.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170105006406/en/
Teva Pharmaceuticals Industries Ltd.IR:United StatesKevin C.
Mannix, 215-591-8912orUnited StatesRan Meir,
215-591-3033orIsraelTomer Amitai, 972 (3)
926-7656orPR:IsraelIris Beck Codner, 972 (3)
926-7687orUnited StatesDenise Bradley, 215-591-8974
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024